
    
      1. To assess the efficacy of FK506 combined with MMF vs intravenous cyclophosphamide (CTX)
           pulses in treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis (LN).

        2. To investigate the safety and tolerability of FK506 combined with MMF vs intravenous CTX
           pulses in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ LN.
    
  